HIMS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. for alleged violations of federal securities laws during the Class Period from April 29, 2025, to June 23, 2025 [1][2]. Group 1: Allegations Against Hims & Hers - The lawsuit claims that Hims & Hers made materially false and misleading statements and failed to disclose adverse facts about its business and operations [3]. - Specific allegations include the deceptive promotion of illegitimate versions of Wegovy® that jeopardized patient safety, risking the termination of its collaboration with Novo Nordisk [3]. - The complaint also states that positive statements made by the company regarding its business prospects were misleading and lacked a reasonable basis [3]. Group 2: Details of Misleading Statements - Allegations include that Hims & Hers misrepresented its communication with Novo Nordisk, suggesting it would ensure continued access to Wegovy for subscribers [4]. - The complaint asserts that Novo approved Hims' offerings of compounded semaglutide products, which were falsely presented as compliant with regulations [4]. - Additionally, it is claimed that Hims & Hers made positive statements about the partnership with Novo and the availability of Wegovy alongside compounded products, which were misleading [4]. Group 3: Next Steps for Investors - Investors who suffered losses in Hims & Hers have until August 25, 2025, to request to be appointed as lead plaintiff in the class action [5]. - The law firm representing the investors operates on a contingency fee basis, meaning they will only collect fees if the case is successful [6].